Supplementary Figures from Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

Supplemental Figure 1: Activation of iCO molecules in T cells enhances NF-κB signaling;Supplemental Figure 2: Activation of iCO molecules enhances cytokine production in T cells;Supplemental Figure 3: CID dose-dependent IL2 production of HER2ζ.iCO T cells can be controlled by CID;Supplemental Figure 4: iCO activation enhances pro-inflammatory cytokine secretion of HER2ζ.iCO T cells;Supplemental Figure 5: Signal 1 is critical for HER2ζ.iCO T-cell effector function;Supplemental Figure 6: HER2ζ.iCO and HER2.CD28ζ T-cell lines have similar T-cell subset composition;Supplemental Figure 7: HER2ζ.iCO T cells have reduced PD-1 surface expression;Supplemental Figure 8: Recurrent tumors from HER2ζ.iCO T-cell + CID and HER2.CD28 ζ T-cell treated mice express HER2;Supplemental Figure 9: HER2ζ.iCO and HER2.CD28ζ T-cell lines have similar T-cell subset composition in vivo;Supplemental Figure 10: Anatomic location of tumors in treated mice;Supplemental Figure 11: Chemokine secretion of A549 cells, and chemokine receptor expression of T cells;Supplemental Figure 12: PD-L1 expression in tumor cell lines;Supplemental Figure 13: Generation of T-cells expressing HER2.CD28ζ.iCO;Supplemental Figure 14: iCO activation enhances expansion and pro-inflammatory cytokine secretion of HER2ζ.iCO and HER2.CD28ζ.iCO T-cells;Supplemental Figure 15: iCO activation enhances cytolytic activity of HER2ζ.iCO and HER2.CD28ζ.iCO T-cells; Supplemental Figure 16: Second CID injection eliminates recurrent tumors in 2/3 mice</p